A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis

• Published in: Haematologica (Roma) Vol. 106; no. 7; pp. 1892 - 1901
• Main Authors: Zhang, Qing, Wei, Ang, Ma, Hong-Hao, Zhang, Li, Lian, Hong-Yun, Wang, Dong, Zhao, Yun-Ze, Cui, Lei, Li, Wei-Jing, Yang, Ying, Wang, Tian-You, Li, Zhi-Gang, Zhang, Rui
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.07.2021; Ferrata Storti Foundation
• Subjects: Hemophagocytic lymphohistiocytosis (HLH); JAK-STATs inhibitor; ruxolitinib; front-line therapy

Hemophagocytic lymphohistiocytosis (HLH) is an immune-regulatory disorder characterized by excessive production of inflammatory cytokines. The treatment recommendations of the HLH-1994 and HLH-2004 protocols have long been used in HLH therapy, but some patients still do not respond well to or have u...